-
Mashup Score: 5
Colonoscopy (CS) is the gold standard to assess postoperative recurrence (POR) in Crohn’s disease (CD). However, CS is invasive and may be poorly tolerated by patients. The aim of this study was to prospectively assess the diagnostic accuracy of a noninvasive approach in detecting POR, using the endoscopic Rutgeerts’ score (RS) as the reference standard.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0VIDEO: Tremfya maintains clinical, endoscopic efficacy through 3 years in Crohn’s disease - 7 month(s) ago
In a Healio video exclusive, Jan Wehkamp, MD, PhD, reports that treatment with Tremfya maintained clinical remission and endoscopic response through 3 years among patients with moderate to severe Crohn’s disease. “There is still tremendous unmet need for patients with inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis,” Wehkamp, vice president and
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
In a @GoHealio #GI 🎥 exclusive from #UEGWeek23: Jan Wehkamp, MD, PhD 👨🏻⚕️, of @JanssenUS, reports that treatment with #Tremfya maintained clinical remission and endoscopic response through 3 years among patients with #Crohnsdisease. Learn more 👇🏼 https://t.co/E2umREDIhy
-
-
Mashup Score: 0Remission Doubled With Risankizumab vs Ustekinumab in CD - 7 month(s) ago
Phase 3b results show risankizumab is superior for endoscopic remission and clinical remission at week 48 compared with ustekinumab, a “once in a career” result, study authors say.
Source: www.medscape.comCategories: General Medicine News, Latest HeadlinesTweet-
Endoscopic remission doubled with risankizumab vs ustekinumab in #CrohnsDisease #GastroTwitter https://t.co/n0fgVPVmeU https://t.co/EX42aWWUm8
-
-
Mashup Score: 0VIVID-1 trial: More than half of mirikizumab users achieve clinical remission in Crohn’s - 7 month(s) ago
Topline findings from the phase 3 VIVID-1 trial showed Eli Lilly’s mirikizumab, an interleukin-23p19 antagonist, demonstrated clinical remission and endoscopic response through 52 weeks in adults with moderate to severe Crohn’s disease. According to a company press release, this was the first double-blind placebo and active controlled trial assessing an IL-23p19 antibody.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
BREAKING🚨: Topline findings from the phase 3 VIVID-1 trial showed @EliLillyandCo’s #mirikizumab, an interleukin-23p19 antagonist, demonstrated clinical remission and endoscopic response through 52 weeks in adults with moderate to severe #Crohnsdisease. https://t.co/0NluSF3FYy
-
-
Mashup Score: 3AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease - 7 month(s) ago
Author links open overlay panel Joseph D. Feuerstein 1, Edith Y. Ho 2, Eugenia Shmidt 3, Harminder Singh 4, Yngve Falck-Ytter 5, Shanaz Sultan 3, Jonathan P. Terdiman
Source: www.sciencedirect.comCategories: Gastroenterology, Latest HeadlinesTweet-
This week's most viewed article: AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal & Perianal Fistulizing #CrohnsDisease: https://t.co/WkaIWDC0dZ By authors at: @BIDMChealth @stanford_gi @umn_dom @umanitoba @cwrusom
-
-
Mashup Score: 0Optimizing Therapies for CD - 10 month(s) ago
Millie Long, Miguel Regueiro, MD, Maia Kayal, MD, Anita Afzali, MD, and David Hudesman, MD, offer clinical strategies for optimizing treatments for Crohn’s Disease (CD) patients.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Hear from our 5-person expert panel as they offer clinical strategies for optimizing treatments for Crohn’s Disease patients: https://t.co/OJaZqwKOYp #Gastroenterology #CrohnsDisease
-
-
Mashup Score: 0‘High-tech, high-touch’ patient care key to improving chronic conditions like Crohn’s - 11 month(s) ago
The prospect of managing a lifelong disease can be daunting, and many patients with chronic conditions struggle with consistent health monitoring, treatment adherence and implementing the changes needed to manage their disease. From the provider perspective, physicians may have limited visibility into how patients are coping with or adhering to treatment regimens — until they present with
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
"For management of chronic #GI conditions like #Crohnsdisease, both high-tech (digitally enabled) and high-touch (#relationship-based) approaches can play key roles in #symptommanagement," Antonio Perez, MD, MBA, FACC, FHFSA, of @ElevanceHealth said. https://t.co/Q5CpK2k6Y9
-
-
Mashup Score: 0Wolters Kluwer Health - 11 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Latest Headlines, PediatricsTweet-
The July issue of JPGN is now out! ⭐ Diagnosis and management of pediatric intestinal pseudo-obstruction ⭐ Porto Group study on endoscopic dilation in #crohnsdisease ⭐ Biomarkers for #biliaryatresia ... and more! 👀 👉 https://t.co/vwM0HyFQro https://t.co/1yKsZYmt04
-
-
Mashup Score: 0‘High-tech, high-touch’ patient care key to improving chronic conditions like Crohn’s - 11 month(s) ago
The prospect of managing a lifelong disease can be daunting, and many patients with chronic conditions struggle with consistent health monitoring, treatment adherence and implementing the changes needed to manage their disease. From the provider perspective, physicians may have limited visibility into how patients are coping with or adhering to treatment regimens — until they present with
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
In an expert editorial, Antonio Perez, MD, MBA, FACC, FHFSA, of @ElevanceHealth discussed ‘high-tech, high-touch’ #patientcare for #CrohnsDisease. #GITwitter #MedTwitter https://t.co/Q5CpK2k6Y9
-
-
Mashup Score: 2More than 60% of Crohn’s patients sustained remission with subcutaneous biosimilar CT-P13 - 11 month(s) ago
CHICAGO — Subcutaneous maintenance therapy with an infliximab biosimilar after IV induction resulted in sustained clinical remission and greater endoscopic response vs. placebo in patients with moderate to severe Crohn’s disease. “In the past several years, there have been a number of formulations of infliximab that have met criteria for what is known as biosimilarity,”
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
Subcutaneous maintenance therapy with an #infliximab biosimilar after IV induction resulted in sustained clinical remission and greater endoscopic response vs. placebo in patients with moderate to severe #Crohnsdisease. #DDW23 @NMH_SHanauerMD https://t.co/SYpUQSBi4D
-
Study examines noninvasive assessment of postoperative disease recurrence in #crohnsdisease. Check out the article here ➡️ https://t.co/sHbYkIcLRL https://t.co/Sta8hSSiNb